In a study combining NIR-PIT with a chemotherapy drug, trastuzumab-IR700 was bound to the highly potent cytotoxic drug, maytansinoid DM1, and targeted HER2 cells in both large and small xenograft tumor models.89 DM1 is a chemotherapy agent that releases catabolites to bind to tubulin upon activation, resulting in mitotic arrest, inhibition of cell growth, and cell death. Here, ERBB2 is linked to neoplasm.